• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

雄激素剥夺联合治疗激素敏感性前列腺癌:一个新领域。

Combination therapy with androgen deprivation for hormone sensitive prostate cancer: A new frontier.

作者信息

Etheridge Tyler, Damodaran Shivashankar, Schultz Adam, Richards Kyle A, Gawdzik Joseph, Yang Bing, Cryns Vincent, Jarrard David F

机构信息

Department of Urology, University of Wisconsin-Madison, Madison, WI, USA.

Department of Medicine, University of Wisconsin-Madison, Madison, WI, USA.

出版信息

Asian J Urol. 2019 Jan;6(1):57-64. doi: 10.1016/j.ajur.2018.09.001. Epub 2018 Sep 15.

DOI:10.1016/j.ajur.2018.09.001
PMID:30775249
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6363606/
Abstract

Androgen deprivation therapy (ADT) has been the standard of care for the last 75 years in metastatic hormone sensitive prostate cancer (PCa). However, this approach is rarely curative. Recent clinical trials have demonstrated that ADT combined with other agents, notably docetaxel and abiraterone, lead to improved survival. The mechanisms surrounding this improved cancer outcomes are incompletely defined. The response of cancer cells to ADT includes apoptosis and cell death, but a significant fraction remains viable. Our laboratory has demonstrated both and that cellular senescence occurs in a subset of these cells. Cellular senescence is a phenotype characterized by cell cycle arrest, senescence-associated β-galactosidase (SA-β-gal), and a hypermetabolic state. Positive features of cellular senescence include growth arrest and immune stimulation, although persistence may release cytokines and growth factors that are detrimental. Senescent tumor cells generate a catabolic state with increased glycolysis, protein turnover and other metabolic changes that represent targets for drugs, like metformin, to be applied in a synthetic lethal approach. This review examines the response to ADT and the putative role of cellular senescence as a biomarker and therapeutic target in this context.

摘要

在过去75年里,雄激素剥夺疗法(ADT)一直是转移性激素敏感性前列腺癌(PCa)的标准治疗方法。然而,这种方法很少能治愈。最近的临床试验表明,ADT与其他药物联合使用,尤其是多西他赛和阿比特龙,可提高生存率。围绕这种改善癌症预后的机制尚未完全明确。癌细胞对ADT的反应包括凋亡和细胞死亡,但仍有相当一部分细胞存活。我们实验室已经证明,在这些细胞的一个亚群中会发生细胞衰老。细胞衰老是一种以细胞周期停滞、衰老相关β-半乳糖苷酶(SA-β-gal)和高代谢状态为特征的表型。细胞衰老的积极特征包括生长停滞和免疫刺激,尽管持续存在可能会释放有害的细胞因子和生长因子。衰老的肿瘤细胞会产生一种分解代谢状态,糖酵解、蛋白质周转和其他代谢变化增加,这些变化代表了像二甲双胍这样的药物在合成致死方法中应用的靶点。本综述探讨了对ADT的反应以及细胞衰老在这种情况下作为生物标志物和治疗靶点的潜在作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1707/6363606/41e5169f755c/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1707/6363606/41e5169f755c/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1707/6363606/41e5169f755c/gr1.jpg

相似文献

1
Combination therapy with androgen deprivation for hormone sensitive prostate cancer: A new frontier.雄激素剥夺联合治疗激素敏感性前列腺癌:一个新领域。
Asian J Urol. 2019 Jan;6(1):57-64. doi: 10.1016/j.ajur.2018.09.001. Epub 2018 Sep 15.
2
Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.靶向转移性激素敏感型前列腺癌:化疗联合激素治疗及新的联合治疗策略
J Urol. 2019 May;201(5):876-885. doi: 10.1097/JU.0000000000000117.
3
Persistence of senescent prostate cancer cells following prolonged neoadjuvant androgen deprivation therapy.长期新辅助雄激素剥夺治疗后衰老前列腺癌细胞的持续存在。
PLoS One. 2017 Feb 24;12(2):e0172048. doi: 10.1371/journal.pone.0172048. eCollection 2017.
4
Stimulation of cellular senescent processes, including secretory phenotypes and anti-oxidant responses, after androgen deprivation therapy in human prostate cancer.雄激素剥夺治疗后人类前列腺癌中细胞衰老过程的刺激,包括分泌表型和抗氧化反应。
J Steroid Biochem Mol Biol. 2017 Jan;165(Pt B):219-227. doi: 10.1016/j.jsbmb.2016.06.007. Epub 2016 Jun 18.
5
Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis.醋酸阿比特龙与多西他赛联合雄激素剥夺疗法治疗高危和转移性激素初治前列腺癌的比较:系统评价和网络荟萃分析。
Eur Urol. 2018 Jun;73(6):834-844. doi: 10.1016/j.eururo.2017.10.002. Epub 2017 Oct 14.
6
Synthetic Lethal Metabolic Targeting of Androgen-Deprived Prostate Cancer Cells with Metformin.二甲双胍靶向雄激素剥夺前列腺癌细胞的合成致死代谢。
Mol Cancer Ther. 2020 Nov;19(11):2278-2287. doi: 10.1158/1535-7163.MCT-19-1141. Epub 2020 Sep 17.
7
Abiraterone acetate/androgen deprivation therapy combination versus docetaxel/androgen deprivation therapy combination in advanced hormone-sensitive prostate cancer: a network meta-analysis on safety and efficacy.醋酸阿比特龙/雄激素剥夺疗法联合方案与多西他赛/雄激素剥夺疗法联合方案治疗晚期激素敏感性前列腺癌的疗效与安全性的网状Meta分析
Curr Med Res Opin. 2018 May;34(5):903-910. doi: 10.1080/03007995.2018.1447450. Epub 2018 Mar 27.
8
The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation.转移性激素敏感型前列腺癌的演变格局:对添加多西他赛或阿比特龙进行雄激素剥夺治疗的证据的批判性评价。
Prostate Cancer Prostatic Dis. 2018 Sep;21(3):306-318. doi: 10.1038/s41391-017-0014-9. Epub 2017 Dec 20.
9
A Cost-effectiveness Analysis of Systemic Therapy for Metastatic Hormone-sensitive Prostate Cancer.转移性激素敏感型前列腺癌系统治疗的成本效益分析
Eur Urol Oncol. 2019 Nov;2(6):649-655. doi: 10.1016/j.euo.2019.01.004. Epub 2019 Jan 30.
10
Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.多西他赛联合雄激素剥夺疗法用于激素敏感性转移性前列腺癌患者:一项系统评价与荟萃分析
Eur Urol. 2016 Apr;69(4):563-573. doi: 10.1016/j.eururo.2015.09.013. Epub 2015 Sep 28.

引用本文的文献

1
Relugolix Plus Enzalutamide For Metastatic Hormone-Sensitive Prostate Cancer: A Case Report.瑞卢戈利联合恩杂鲁胺治疗转移性激素敏感性前列腺癌:一例报告
Res Rep Urol. 2024 Oct 9;16:245-252. doi: 10.2147/RRU.S485238. eCollection 2024.
2
Management of Advanced Prostate Cancer With Relugolix: Illustrative Case Scenarios From an Advanced Practice Provider Perspective.使用瑞卢戈利治疗晚期前列腺癌:从高级执业提供者角度看的实例情况
J Adv Pract Oncol. 2024 Jan;15(1):43-55. doi: 10.6004/jadpro.2024.15.1.5. Epub 2024 Jan 1.
3
Emergent dynamics of underlying regulatory network links EMT and androgen receptor-dependent resistance in prostate cancer.

本文引用的文献

1
Metformin Use is Associated with Improved Survival for Patients with Advanced Prostate Cancer on Androgen Deprivation Therapy.二甲双胍的使用与雄激素剥夺治疗的晚期前列腺癌患者的生存改善相关。
J Urol. 2018 Dec;200(6):1256-1263. doi: 10.1016/j.juro.2018.06.031. Epub 2018 Jun 22.
2
Abiraterone acetate in the treatment of prostate cancer.醋酸阿比特龙治疗前列腺癌。
Biomed Pharmacother. 2018 May;101:211-218. doi: 10.1016/j.biopha.2018.02.067. Epub 2018 Feb 26.
3
Senescence-associated reprogramming promotes cancer stemness.衰老相关重编程促进癌症干性。
潜在调控网络的紧急动力学将前列腺癌中的上皮-间质转化与雄激素受体依赖性耐药联系起来。
Comput Struct Biotechnol J. 2023 Feb 8;21:1498-1509. doi: 10.1016/j.csbj.2023.01.031. eCollection 2023.
4
Tautomycin and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer.曲古抑菌素和恩杂鲁胺联合使用对去势抵抗性前列腺癌产生协同作用。
Cell Death Discov. 2022 Nov 29;8(1):471. doi: 10.1038/s41420-022-01257-1.
5
Prostate cancer cells demonstrate unique metabolism and substrate adaptability acutely after androgen deprivation therapy.前列腺癌细胞在雄激素剥夺治疗后表现出独特的代谢和底物适应性。
Prostate. 2022 Dec;82(16):1547-1557. doi: 10.1002/pros.24428. Epub 2022 Aug 18.
6
Androgen-targeting therapeutics mitigate the adverse effect of GnRH agonist on the risk of neurodegenerative disease in men treated for prostate cancer.雄激素靶向治疗可减轻 GnRH 激动剂治疗前列腺癌男性患者发生神经退行性疾病风险的不良影响。
Cancer Med. 2022 Jul;11(13):2687-2698. doi: 10.1002/cam4.4650. Epub 2022 Mar 16.
7
At the Bench: Pre-clinical evidence for multiple functions of CXCR4 in cancer.在实验台上:CXCR4 在癌症中的多种功能的临床前证据。
J Leukoc Biol. 2021 May;109(5):969-989. doi: 10.1002/JLB.2BT1018-715RR. Epub 2020 Oct 26.
8
In honor of Dr. Donald S. Coffey - Prostate cancer biology and therapy.向唐纳德·S·科菲博士致敬——前列腺癌生物学与治疗
Asian J Urol. 2019 Jan;6(1):1-2. doi: 10.1016/j.ajur.2018.10.002. Epub 2018 Nov 3.
Nature. 2018 Jan 4;553(7686):96-100. doi: 10.1038/nature25167. Epub 2017 Dec 20.
4
Enhanced radiosensitization of enzalutamide via schedule dependent administration to androgen-sensitive prostate cancer cells.通过依给药方案给药增强恩杂鲁胺对雄激素敏感前列腺癌细胞的放射增敏作用。
Prostate. 2018 Jan;78(1):64-75. doi: 10.1002/pros.23445. Epub 2017 Nov 14.
5
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.阿比特龙用于既往未接受过激素治疗的前列腺癌患者
N Engl J Med. 2017 Jul 27;377(4):338-351. doi: 10.1056/NEJMoa1702900. Epub 2017 Jun 3.
6
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.阿比特龙联合泼尼松治疗转移性去势敏感性前列腺癌。
N Engl J Med. 2017 Jul 27;377(4):352-360. doi: 10.1056/NEJMoa1704174. Epub 2017 Jun 4.
7
Persistence of senescent prostate cancer cells following prolonged neoadjuvant androgen deprivation therapy.长期新辅助雄激素剥夺治疗后衰老前列腺癌细胞的持续存在。
PLoS One. 2017 Feb 24;12(2):e0172048. doi: 10.1371/journal.pone.0172048. eCollection 2017.
8
Cancer Statistics, 2017.《2017 年癌症统计》
CA Cancer J Clin. 2017 Jan;67(1):7-30. doi: 10.3322/caac.21387. Epub 2017 Jan 5.
9
Targeting cancer-related inflammation in the era of immunotherapy.免疫疗法时代针对癌症相关炎症的研究
Immunol Cell Biol. 2017 Apr;95(4):325-332. doi: 10.1038/icb.2016.126. Epub 2017 Jan 10.
10
Additive inhibitory effects of simvastatin and enzalutamide on androgen-sensitive LNCaP and VCaP prostate cancer cells.辛伐他汀和恩杂鲁胺对雄激素敏感的LNCaP和VCaP前列腺癌细胞的相加抑制作用。
Biochem Biophys Res Commun. 2016 Dec 2;481(1-2):46-50. doi: 10.1016/j.bbrc.2016.11.021. Epub 2016 Nov 8.